Celltrion, Inc. (068270.KS)
- Previous Close
177,400.00 - Open
177,500.00 - Bid --
- Ask --
- Day's Range
176,300.00 - 178,800.00 - 52 Week Range
131,000.00 - 241,000.00 - Volume
246,628 - Avg. Volume
636,245 - Market Cap (intraday)
36.53T - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield 500.00 (0.28%)
- Ex-Dividend Date Dec 27, 2023
- 1y Target Est
229,929.00
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
www.celltrion.comRecent News: 068270.KS
Performance Overview: 068270.KS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 068270.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 068270.KS
Valuation Measures
Market Cap
36.53T
Enterprise Value
37.66T
Trailing P/E
47.06
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.58
Price/Book (mrq)
2.15
Enterprise Value/Revenue
17.30
Enterprise Value/EBITDA
40.65
Financial Highlights
Profitability and Income Statement
Profit Margin
24.61%
Return on Assets (ttm)
3.16%
Return on Equity (ttm)
5.04%
Revenue (ttm)
2.18T
Net Income Avi to Common (ttm)
535.65B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
757.5B
Total Debt/Equity (mrq)
11.04%
Levered Free Cash Flow (ttm)
-1.45T
Research Analysis: 068270.KS
Company Insights: 068270.KS
068270.KS does not have Company Insights